Skip to main content
editorial
. 2023 Aug 18;7(1):e184. doi: 10.1017/cts.2023.612

Table 1.

Possible unintended consequences of supervised or unsupervised use of oral GLP-1 receptor agonists in children and adolescents

Adverse effect Reason for concern
Long-term consequences on growth and development Balance of energy intake and energy expenditure modulate critical growth hormones such as GH and IGF-1. The appetite suppressant, anti-hedonic, and fatigue effects of the GLP-1RA may alter this balance during critical periods of growth and development.
Abuse among patients with diagnosed eating disorders Pediatric-aged patients (male and female) with eating disorders are known to abuse appetite suppressants.
Abuse among children and adolescents in certain competitive sports (e.g., wrestling, martial arts, gymnastics, ballet) Children and adolescents involved in school, club, or community sports like wrestling or gymnastics where body weight is a competitive factor are known to engage in unhealthy behaviors to accelerate weight loss.
Unsupervised use for unwarranted self-perception of obesity and overweight, particularly among female adolescents Inaccurate perception of being overweight in healthy-weight adolescents result in unnecessary weight control behaviors [29]. In children and young adults, supplements sold for weight loss, muscle building, and energy were associated with almost three times the risk for severe medical outcomes compared with vitamins [30].
Excessive or insufficient medical prescription in populations with high prevalence of obesity and poor fitness Pediatricians have little or no formal training in effective ways to deal with obesity, overweight, or poor physical fitness in their patients. Short-term effectiveness and convenience of drug prescriptions may be well intended but lead to untested effects when used for longer duration during critical periods of growth and development.
Distorted cost-benefit relationship of long-term use in youth
  • Result in disparities in GLP-1RA availability

  • Promote counterfeit or drug diversion activity.

  • Off-label utilization may not be covered by insurers.

  • Possible lifelong therapy may be cost-prohibitive.